Cerebrospinal-fluid Orexin-A levels in different neurocognitive disorders: a comparison study

Area of Science:

• Neuroscience
• Neurology
• Biochemistry

Background:

• Orexin-A is a neuropeptide involved in regulating sleep-wake cycles and appetite.
• Neurocognitive disorders, including Alzheimer's disease (AD) and frontotemporal dementia (FTD), are associated with complex neurological and behavioral changes.
• Alterations in cerebrospinal fluid (CSF) biomarkers are crucial for understanding disease mechanisms and developing diagnostic tools.

Purpose of the Study:

• To investigate and compare CSF orexin-A levels in patients with various neurocognitive disorders.
• To explore potential correlations between CSF orexin-A levels and specific disease characteristics.
• To assess the diagnostic utility of CSF orexin-A in differentiating neurocognitive disorders.

Main Methods:

• Collected CSF samples from 214 participants, including patients with mild AD (mAD), moderate to severe AD (msAD), behavioral variants of FTD (bv-FTD), non-fluent primary aphasia (NFPA), idiopathic normal pressure hydrocephalus (iNPH), and healthy elderly controls.
• Quantified CSF orexin-A concentrations using a validated assay.
• Performed statistical analyses to compare orexin-A levels across groups and with controls.

Main Results:

• Idiopathic normal pressure hydrocephalus (iNPH) patients exhibited the highest CSF orexin-A levels.
• Patients with NFPA, iNPH, and msAD showed significantly higher CSF orexin-A concentrations than controls.
• Mild AD (mAD) patients displayed lower CSF orexin-A levels than controls and all other patient groups, suggesting a distinct orexinergic profile.

Conclusions:

• CSF orexin-A levels vary significantly among different neurocognitive disorders.
• Observed differences may be linked to impaired sleep-wake cycles, behavioral disturbances, and altered CSF dynamics.
• Targeting the orexin system represents a potential therapeutic avenue for neurocognitive disorders.